TPTakeda PharmaceuticalView brand email archive

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations email from Takeda Pharmaceutical screenshot
Screenshot preview · Scroll to view the full email

Archived for design inspiration. Original email and brand assets belong to their respective owners. Design observations describe the creative; they are not campaign results.